Neuro-X seminar: Prof Anne Andrews - Personalized medicine and predictive health and wellness: Adding the chemical component
Event details
| Date | 09.07.2024 |
| Hour | 12:15 › 13:15 |
| Speaker | Prof Anne Andrews |
| Location | Online |
| Category | Conferences - Seminars |
| Event Language | English |
ABSTRACT
Wearable sensors that detect and quantify biomarkers in retrievable biofluids (e.g., interstitial fluid, sweat, tears) provide information on human dynamic physiological and psychological states. This information can transform health and wellness by providing actionable feedback. Due to outdated and insufficiently sensitive technologies, current on-body sensing systems have capabilities limited to pH, and a few high-concentration electrolytes, metabolites, and nutrients. As such, wearable sensing systems cannot detect key low-concentration biomarkers indicative of stress, inflammation, metabolic, and reproductive status.
We are revolutionizing sensing. Our electronic biosensors detect virtually any signaling molecule or metabolite at ultra-low levels. We have monitored serotonin, dopamine, cortisol, phenylalanine, estradiol, progesterone, and glucose in blood, sweat, interstitial fluid, and tears. The sensors are based on modern nanoscale semiconductor transistors that are straightforwardly scalable for manufacturing. We are developing sensors for >40 biomarkers for personalized continuous monitoring (e.g., smartwatch, wearable patch) that will provide feedback for treating chronic health conditions (e.g., perimenopause, stress disorders, phenylketonuria). Moreover, our sensors will enable female fertility monitoring and the adoption of more healthy lifestyles to prevent disease and improve physical and cognitive performance.
BIO
Dr. Andrews is Professor of Psychiatry & Biobehavioral Sciences and Chemistry & Biochemistry at the University of California, Los Angeles. She is a member of the Semel Institute for Neuroscience & Human Behavior, the Hatos Center for Neuropharmacology, and the California NanoSystems Institute. Andrews received a B.S. from the Pennsylvania State University and a Ph.D. in Chemistry from the American University as a U.S. Department of Education Fellow and while working at the National Institute of Mental Health. She was later a postdoctoral fellow and senior staff fellow at the NIMH. There, Andrews discovered and characterized a novel serotonin neurotoxin, 2’-NH2-MPTP. She was also a member of the team that developed and characterized the first serotonin transporter-deficient mouse model (aka SERT knockout mice).
Andrews is a recipient of an NIH Director’s Transformative Research Award. She received a California Neurotechnologies Research Award, a NARSAD Independent Investigator Award, an American Parkinson’s Disease Association Research Award, an Eli Lily Outstanding Young Analytical Chemist Award, and an NIH Fellows Award for Research Excellence, among others. She was Associate Editor for ACS Chemical Neuroscience and is currently a Fellow of the American College of Neuropsychopharmacology and President of the International Society for Serotonin Research.
Wearable sensors that detect and quantify biomarkers in retrievable biofluids (e.g., interstitial fluid, sweat, tears) provide information on human dynamic physiological and psychological states. This information can transform health and wellness by providing actionable feedback. Due to outdated and insufficiently sensitive technologies, current on-body sensing systems have capabilities limited to pH, and a few high-concentration electrolytes, metabolites, and nutrients. As such, wearable sensing systems cannot detect key low-concentration biomarkers indicative of stress, inflammation, metabolic, and reproductive status.
We are revolutionizing sensing. Our electronic biosensors detect virtually any signaling molecule or metabolite at ultra-low levels. We have monitored serotonin, dopamine, cortisol, phenylalanine, estradiol, progesterone, and glucose in blood, sweat, interstitial fluid, and tears. The sensors are based on modern nanoscale semiconductor transistors that are straightforwardly scalable for manufacturing. We are developing sensors for >40 biomarkers for personalized continuous monitoring (e.g., smartwatch, wearable patch) that will provide feedback for treating chronic health conditions (e.g., perimenopause, stress disorders, phenylketonuria). Moreover, our sensors will enable female fertility monitoring and the adoption of more healthy lifestyles to prevent disease and improve physical and cognitive performance.
BIO
Dr. Andrews is Professor of Psychiatry & Biobehavioral Sciences and Chemistry & Biochemistry at the University of California, Los Angeles. She is a member of the Semel Institute for Neuroscience & Human Behavior, the Hatos Center for Neuropharmacology, and the California NanoSystems Institute. Andrews received a B.S. from the Pennsylvania State University and a Ph.D. in Chemistry from the American University as a U.S. Department of Education Fellow and while working at the National Institute of Mental Health. She was later a postdoctoral fellow and senior staff fellow at the NIMH. There, Andrews discovered and characterized a novel serotonin neurotoxin, 2’-NH2-MPTP. She was also a member of the team that developed and characterized the first serotonin transporter-deficient mouse model (aka SERT knockout mice).
Andrews is a recipient of an NIH Director’s Transformative Research Award. She received a California Neurotechnologies Research Award, a NARSAD Independent Investigator Award, an American Parkinson’s Disease Association Research Award, an Eli Lily Outstanding Young Analytical Chemist Award, and an NIH Fellows Award for Research Excellence, among others. She was Associate Editor for ACS Chemical Neuroscience and is currently a Fellow of the American College of Neuropsychopharmacology and President of the International Society for Serotonin Research.
Practical information
- Informed public
- Free